(NASDAQ: SEPN) Septerna's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.26%.
Septerna's earnings in 2026 is -$48,879,000.On average, 10 Wall Street analysts forecast SEPN's earnings for 2026 to be -$56,855,960, with the lowest SEPN earnings forecast at -$96,378,060, and the highest SEPN earnings forecast at $1,886,068. On average, 9 Wall Street analysts forecast SEPN's earnings for 2027 to be -$83,364,193, with the lowest SEPN earnings forecast at -$116,621,853, and the highest SEPN earnings forecast at -$29,705,566.
In 2028, SEPN is forecast to generate -$88,860,733 in earnings, with the lowest earnings forecast at -$85,375,998 and the highest earnings forecast at -$91,474,284.